PERSEUS Trial Findings at EHA 2024

EP: 1.Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024

EP: 2.EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

Now Viewing

EP: 3.PERSEUS Trial Findings at EHA 2024

EP: 4.Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

EP: 5.EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

EP: 6.EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

EP: 7.Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Video content above is prompted by the following:

• Discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on minimal residual disease (MRD) in the PERSEUS trial of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by daratumumab/lenalidomide (D-R) in patients with newly diagnosed multiple myeloma.
  • What was the objective of this study?
  • How was this study designed/what methodology was used?
  • What results were presented?
• Please provide your key takeaways from this study. How might these findings impact the management of patients with multiple myeloma?
• How have the criteria for multiple myeloma patients to be considered transplant-eligible or -ineligible evolved in recent history? How do you evaluate transplant eligibility in your practice?